THE NEWSROOM

Search
Categories
Archives

Investment Monitoring From Robbins LLP

To ensure your financial investments are being managed honestly, enroll in Stock Watch, our free investment monitoring service for individual and institutional investors.

Investigation of GTT Communications

GTT Communications, Inc. (GTT) Accused of Misleading Investors According to the complaint, for alleged violations of the Securities Exchange Act of 1934 between February 26, 2018 and July 1, 2019,

Read More

Investigation of National Beverage Corp.

Robbins LLP is Investigating the Officers and Directors of National Beverage Corp. (FIZZ) on behalf of Shareholders Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors

Read More

Investigation of Aclaris Therapeutics

Aclaris Therapeutics, Inc. (ACRS) Accused of Making Misleading Claims in Video Advertisement According to the complaint for alleged violations of the Securities Exchange Act of 1934 between May 8, 2018

Read More

Investigation of Greenlane Holdings, Inc.

Robbins LLP is Investigating Greenlane Holdings, Inc. (GNLN) Shareholder rights law firm Robbins LLP informs shareholders that it is investigating Greenlane Holdings, Inc. (NASDAQ: GNLN) for potential violations of federal

Read More

Shareholder Investigation of American Renal

American Renal Associates Holdings, Inc. (ARA) Accused of Improper Revenue Recognition According to the complaint, American Renal Associates Holdings, Inc’s (ARA) officers and directors breached their fiduciary duties by failing

Read More

Investigation of Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc. (VNDA) Used its Drugs for Off-Label Purposes According to the complaint, since November 2015, Vanda Pharmaceuticals Inc (VNDA) and its officers have breached their fiduciary duties by

Read More

Karyopharm Therapeutics, Inc.

Karyopharm Therapeutics Inc. (KPTI) Accused of Misleading Investors According to the complaint, in March 2017, Karyopharm reported that its interim results from its SORPA study of selinexor did not reach

Read More
Skip to content